This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Benhorin, J. Articles by Medina, A. Search for Related Content PubMed PubMed Citation Articles by Benhorin, J. Articles by Medina, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Genetics Home Reference Hazardous Substances DB LIDOCAINE Related Collections Clinical genetics Cardiovascular Pharmacology Arrhythmias, clinical electrophysiology, drugs Genetics of cardiovascular disease

(Circulation. 2000;101:1698.)
© 2000 American Heart Association, Inc.

Clinical Investigation and Reports

Effects of Flecainide in Patients With New SCN5A Mutation

Mutation-Specific Therapy for Long-QT Syndrome?

J. Benhorin, MD; R. Taub, RN; M. Goldmit, MSc; B. Kerem, PhD; R. S. Kass, PhD; I. Windman, PhD; A. Medina, MD

From the Department of Cardiology (J.B., R.T., I.W., A.M.), Bikur Cholim Hospital, and the Department of Genetics (M.G., B.K.), the Hebrew University, Jerusalem, Israel; and the Department of Pharmacology (R.S.K.), Columbia University College of Physicians and Surgeons, New York, NY.

Correspondence to J. Benhorin, MD, The Heiden Department of Cardiology, Bikur Cholim Hospital, PO Box 492, Jerusalem 91004, Israel. E-mail benhorin{at}md2.huji.ac.il

Background—Mutations in the cardiac sodium channel gene (SCN5A) can cause one variant of the congenital long-QT syndrome. The effects of some of these mutations on the -subunit channel properties can be blocked by type Ib antiarrhythmic drugs. Recently, we have described a new SCN5A mutation (D1790G) that affects the channel properties in a manner suggesting that sodium blockers of the Ib type will be ineffective in carriers of this mutation. Hence, the ECG effects of flecainide-acetate, a type Ic sodium blocker, were evaluated in carriers of this mutation.

Methods and Results—Eight asymptomatic mutation carriers and 5 control subjects were studied. Intravenous lidocaine was tested first in only 2 mutation carriers and had no significant effect on any ECG parameter. Flecainide significantly shortened all heart rate–corrected repolarization duration parameters only in carriers and not in control subjects: QT_c shortened by 9.5% (from 517±45 to 468±36 ms, P=0.011), and the S-offset to T-onset interval shortened by 64.7% (from 187±88 to 66±50 ms, P=0.0092). Flecainide also normalized the marked baseline repolarization dispersion in most mutation carriers. These effects among carriers were maintained during long-term (9 to 17 months) outpatient flecainide therapy with no adverse effects.

Conclusions—This report is the first to describe SCN5A mutation carriers who significantly responded to flecainide therapy yet did not respond to lidocaine. These results have important implications for long-QT allele–specific therapeutic strategies.

Key Words: long-QT syndrome • genetics • sodium (ion) channels

This article has been cited by other articles:

				D. M. Roden Long-QT Syndrome N. Engl. J. Med., January 10, 2008; 358(2): 169 - 176. [Full Text] [PDF]

				Y. Ruan, N. Liu, R. Bloise, C. Napolitano, and S. G. Priori Gating Properties of SCN5A Mutations and the Response to Mexiletine in Long-QT Syndrome Type 3 Patients Circulation, September 4, 2007; 116(10): 1137 - 1144. [Abstract] [Full Text] [PDF]

				K. S. Stokoe, R. Balasubramaniam, C. A. Goddard, W. H. Colledge, A. A. Grace, and C. L.-H. Huang Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/ murine hearts modelling the Brugada syndrome J. Physiol., May 15, 2007; 581(1): 255 - 275. [Abstract] [Full Text] [PDF]

				K. S. Stokoe, G. Thomas, C. A. Goddard, W. H. Colledge, A. A. Grace, and C. L.-H. Huang Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/{Delta} murine hearts modelling long QT syndrome 3 J. Physiol., January 1, 2007; 578(1): 69 - 84. [Abstract] [Full Text] [PDF]

				S. Fredj, N. Lindegger, K. J. Sampson, P. Carmeliet, and R. S. Kass Altered Na+ Channels Promote Pause-Induced Spontaneous Diastolic Activity in Long QT Syndrome Type 3 Myocytes Circ. Res., November 24, 2006; 99(11): 1225 - 1232. [Abstract] [Full Text] [PDF]

				Y. Zhu, J. W. Kyle, and P. J. Lee Flecainide sensitivity of a Na channel long QT mutation shows an open-channel blocking mechanism for use-dependent block Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H29 - H37. [Abstract] [Full Text] [PDF]

				E. S. Kaufman Efficient Genotyping for Congenital Long QT Syndrome JAMA, December 21, 2005; 294(23): 3027 - 3028. [Full Text] [PDF]

				G. S. Ginsburg, M. P. Donahue, and L. K. Newby Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1615 - 1627. [Abstract] [Full Text] [PDF]

				J. M. Nerbonne and R. S. Kass Molecular Physiology of Cardiac Repolarization Physiol Rev, October 1, 2005; 85(4): 1205 - 1253. [Abstract] [Full Text] [PDF]

				S Chakrabarti and A G Stuart Understanding cardiac arrhythmias Arch. Dis. Child., October 1, 2005; 90(10): 1086 - 1090. [Abstract] [Full Text] [PDF]

				W. Shimizu The long QT syndrome: Therapeutic implications of a genetic diagnosis Cardiovasc Res, August 15, 2005; 67(3): 347 - 356. [Abstract] [Full Text] [PDF]

				E. Ramos and M. E O'Leary State-dependent trapping of flecainide in the cardiac sodium channel J. Physiol., October 1, 2004; 560(1): 37 - 49. [Abstract] [Full Text] [PDF]

				J.-F. Desaphy, A. D. E. Luca, M. P. Didonna, A. L. George Jr, and D. C. Camerino Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block J. Physiol., January 15, 2004; 554(2): 321 - 334. [Abstract] [Full Text] [PDF]

				M. W. Veldkamp, R. Wilders, A. Baartscheer, J. G. Zegers, C. R. Bezzina, and A. A.M. Wilde Contribution of Sodium Channel Mutations to Bradycardia and Sinus Node Dysfunction in LQT3 Families Circ. Res., May 16, 2003; 92(9): 976 - 983. [Abstract] [Full Text] [PDF]

				P. E. Light, C. H.R. Wallace, and J. R.B. Dyck Constitutively Active Adenosine Monophosphate-Activated Protein Kinase Regulates Voltage-Gated Sodium Channels in Ventricular Myocytes Circulation, April 22, 2003; 107(15): 1962 - 1965. [Abstract] [Full Text] [PDF]

				H. L Tan, C. R Bezzina, J. P.P Smits, A. O Verkerk, and A. A.M Wilde Genetic control of sodium channel function Cardiovasc Res, March 15, 2003; 57(4): 961 - 973. [Abstract] [Full Text] [PDF]

				H. Liu, J. Atkins, and R. S. Kass Common Molecular Determinants of Flecainide and Lidocaine Block of Heart Na+ Channels: Evidence from Experiments with Neutral and Quaternary Flecainide Analogues J. Gen. Physiol., February 24, 2003; 121(3): 199 - 214. [Abstract] [Full Text] [PDF]

				C. R. Bezzina, M. B. Rook, W.A. Groenewegen, L. J. Herfst, A. C. van der Wal, J. Lam, H. J. Jongsma, A. A.M. Wilde, and M. M.A.M. Mannens Compound Heterozygosity for Mutations (W156X and R225W) in SCN5A Associated With Severe Cardiac Conduction Disturbances and Degenerative Changes in the Conduction System Circ. Res., February 7, 2003; 92(2): 159 - 168. [Abstract] [Full Text] [PDF]

				C.-j. Liu, S. D. Dib-Hajj, M. Renganathan, T. R. Cummins, and S. G. Waxman Modulation of the Cardiac Sodium Channel Nav1.5 by Fibroblast Growth Factor Homologous Factor 1B J. Biol. Chem., January 3, 2003; 278(2): 1029 - 1036. [Abstract] [Full Text] [PDF]

				E. Moric, E. Herbert, M. Trusz-Gluza, A. Filipecki, U. Mazurek, and T. Wilczok The implications of genetic mutations in the sodium channel gene (SCN5A) Europace, January 1, 2003; 5(4): 325 - 334. [Abstract] [Full Text] [PDF]

				X. H.T. Wehrens, M. A. Vos, P. A. Doevendans, and H. J.J. Wellens Novel Insights in the Congenital Long QT Syndrome Ann Intern Med, December 17, 2002; 137(12): 981 - 992. [Abstract] [Full Text] [PDF]

				H. Liu, M. Tateyama, C. E. Clancy, H. Abriel, and R. S. Kass Channel Openings Are Necessary but not Sufficient for Use-dependent Block of Cardiac Na+ Channels by Flecainide: Evidence from the Analysis of Disease-linked Mutations J. Gen. Physiol., June 24, 2002; 120(1): 39 - 51. [Abstract] [Full Text] [PDF]

				J. R. Balser Inherited sodium channelopathies: models for acquired arrhythmias? Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1175 - H1180. [Full Text] [PDF]

				I. Deschenes, N. Neyroud, D. DiSilvestre, E. Marban, D. T. Yue, and G. F. Tomaselli Isoform-Specific Modulation of Voltage-Gated Na+ Channels by Calmodulin Circ. Res., March 8, 2002; 90 (4): e49 - e57. [Abstract] [Full Text] [PDF]

				G. Subramanian, M. D. Adams, J. C. Venter, and S. Broder Implications of the Human Genome for Understanding Human Biology and Medicine JAMA, November 14, 2001; 286(18): 2296 - 2307. [Abstract] [Full Text] [PDF]

				S. G. Priori, C. Napolitano, P. J. Schwartz, R. Bloise, L. Crotti, and E. Ronchetti The Elusive Link Between LQT3 and Brugada Syndrome : The Role of Flecainide Challenge Circulation, August 29, 2000; 102(9): 945 - 947. [Abstract] [Full Text] [PDF]

				H. Abriel, X. H. T. Wehrens, J. Benhorin, B. Kerem, and R. S. Kass Molecular Pharmacology of the Sodium Channel Mutation D1790G Linked to the Long-QT Syndrome Circulation, August 22, 2000; 102(8): 921 - 925. [Abstract] [Full Text] [PDF]

				X. H. T. Wehrens, H. Abriel, C. Cabo, J. Benhorin, and R. S. Kass Arrhythmogenic Mechanism of an LQT-3 Mutation of the Human Heart Na+ Channel {alpha}-Subunit : A Computational Analysis Circulation, August 1, 2000; 102(5): 584 - 590. [Abstract] [Full Text] [PDF]